These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

41 related articles for article (PubMed ID: 27283790)

  • 1. Discovery of a 2-hydroxyacetophenone derivative as an outstanding linker to enhance potency and β-selectivity of liver X receptor agonist.
    Koura M; Yamaguchi Y; Kurobuchi S; Sumida H; Watanabe Y; Enomoto T; Matsuda T; Okuda A; Koshizawa T; Matsumoto Y; Shibuya K
    Bioorg Med Chem; 2016 Aug; 24(16):3436-46. PubMed ID: 27283790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and discovery of 2-oxochromene derivatives as liver X receptor β-selective agonists.
    Matsuda T; Okuda A; Watanabe Y; Miura T; Ozawa H; Tosaka A; Yamazaki K; Yamaguchi Y; Kurobuchi S; Koura M; Shibuya K
    Bioorg Med Chem Lett; 2015 Mar; 25(6):1274-8. PubMed ID: 25677664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of Tetrachlorophthalimides as Liver X Receptor β (LXRβ)-Selective Agonists.
    Nomura S; Endo-Umeda K; Makishima M; Hashimoto Y; Ishikawa M
    ChemMedChem; 2016 Oct; 11(20):2347-2360. PubMed ID: 27690261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis and pharmacology of 1,1-bistrifluoromethylcarbinol derivatives as liver X receptor β-selective agonists.
    Koura M; Matsuda T; Okuda A; Watanabe Y; Yamaguchi Y; Kurobuchi S; Matsumoto Y; Shibuya K
    Bioorg Med Chem Lett; 2015 Jul; 25(13):2668-74. PubMed ID: 25998501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cellular Cholesterol Accumulation Facilitates Ubiquitination and Lysosomal Degradation of Cell Surface-Resident ABCA1.
    Mizuno T; Hayashi H; Kusuhara H
    Arterioscler Thromb Vasc Biol; 2015 Jun; 35(6):1347-56. PubMed ID: 25838426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Feeding probiotic Lactobacillus paracasei to Ossabaw pigs on a high-fat diet prevents cholesteryl-ester accumulation and LPS modulation of the Liver X receptor and inflammatory axis in alveolar macrophages.
    Trasino SE; Dawson HD; Urban JF; Wang TT; Solano-Aguilar G
    J Nutr Biochem; 2013 Nov; 24(11):1931-9. PubMed ID: 24060267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel peroxisome proliferator-activated receptor alpha agonists lower low-density lipoprotein and triglycerides, raise high-density lipoprotein, and synergistically increase cholesterol excretion with a liver X receptor agonist.
    Mukherjee R; Locke KT; Miao B; Meyers D; Monshizadegan H; Zhang R; Search D; Grimm D; Flynn M; O'Malley KM; Zhang L; Li J; Shi Y; Kennedy LJ; Blanar M; Cheng PT; Tino J; Srivastava RA
    J Pharmacol Exp Ther; 2008 Dec; 327(3):716-26. PubMed ID: 18799592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Skeletal muscle as a target of LXR agonist after long-term treatment: focus on lipid homeostasis.
    Archer A; Laurencikiene J; Ahmed O; Steffensen KR; Parini P; Gustafsson JÅ; Korach-André M
    Am J Physiol Endocrinol Metab; 2014 Mar; 306(5):E494-502. PubMed ID: 24368671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural development of tetrachlorophthalimides as liver X receptor β (LXRβ)-selective agonists with improved aqueous solubility.
    Nomura S; Endo-Umeda K; Fujii S; Makishima M; Hashimoto Y; Ishikawa M
    Bioorg Med Chem Lett; 2018 Feb; 28(4):796-801. PubMed ID: 29398545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liver X receptor (LXR) partial agonists: biaryl pyrazoles and imidazoles displaying a preference for LXRβ.
    Kick E; Martin R; Xie Y; Flatt B; Schweiger E; Wang TL; Busch B; Nyman M; Gu XH; Yan G; Wagner B; Nanao M; Nguyen L; Stout T; Plonowski A; Schulman I; Ostrowski J; Kirchgessner T; Wexler R; Mohan R
    Bioorg Med Chem Lett; 2015 Jan; 25(2):372-7. PubMed ID: 25435151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dietary phosphate restriction induces hepatic lipid accumulation through dysregulation of cholesterol metabolism in mice.
    Tanaka S; Yamamoto H; Nakahashi O; Kagawa T; Ishiguro M; Masuda M; Kozai M; Ikeda S; Taketani Y; Takeda E
    Nutr Res; 2013 Jul; 33(7):586-93. PubMed ID: 23827134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery and SAR study of hydroxyacetophenone derivatives as potent, non-steroidal farnesoid X receptor (FXR) antagonists.
    Liu P; Xu X; Chen L; Ma L; Shen X; Hu L
    Bioorg Med Chem; 2014 Mar; 22(5):1596-607. PubMed ID: 24513188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dynamic changes of Apo A1 mediated by LXR/RXR/ABCA1 pathway in brains of the aging rats with cerebral hypoperfusion.
    Wang L; Zhang X; Lü Y; Tian M; Li Y
    Brain Res Bull; 2014 Jan; 100():84-92. PubMed ID: 24291698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LXR{beta} is the dominant LXR subtype in skeletal muscle regulating lipogenesis and cholesterol efflux.
    Hessvik NP; Boekschoten MV; Baltzersen MA; Kersten S; Xu X; Andersén H; Rustan AC; Thoresen GH
    Am J Physiol Endocrinol Metab; 2010 Mar; 298(3):E602-13. PubMed ID: 19996385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monascin and ankaflavin act as natural AMPK activators with PPARα agonist activity to down-regulate nonalcoholic steatohepatitis in high-fat diet-fed C57BL/6 mice.
    Hsu WH; Chen TH; Lee BH; Hsu YW; Pan TM
    Food Chem Toxicol; 2014 Feb; 64():94-103. PubMed ID: 24275089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 4-(3-aryloxyaryl)quinoline alcohols are liver X receptor agonists.
    Bernotas RC; Kaufman DH; Singhaus RR; Ullrich J; Unwalla R; Quinet E; Nambi P; Wilhelmsson A; Goos-Nilsson A; Wrobel J
    Bioorg Med Chem; 2009 Dec; 17(23):8086-92. PubMed ID: 19853462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Indazole-based liver X receptor (LXR) modulators with maintained atherosclerotic lesion reduction activity but diminished stimulation of hepatic triglyceride synthesis.
    Wrobel J; Steffan R; Bowen SM; Magolda R; Matelan E; Unwalla R; Basso M; Clerin V; Gardell SJ; Nambi P; Quinet E; Reminick JI; Vlasuk GP; Wang S; Feingold I; Huselton C; Bonn T; Farnegardh M; Hansson T; Nilsson AG; Wilhelmsson A; Zamaratski E; Evans MJ
    J Med Chem; 2008 Nov; 51(22):7161-8. PubMed ID: 18973288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis of 4-(3-biaryl)quinoline sulfones as potent liver X receptor agonists.
    Ullrich JW; Morris R; Bernotas RC; Travins JM; Jetter J; Unwalla R; Quinet E; Nambi P; Feingold I; Huselton C; Enroth C; Wilhelmsson A; Goos-Nilsson A; Wrobel J
    Bioorg Med Chem Lett; 2010 May; 20(9):2903-7. PubMed ID: 20382019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatic TRAP80 selectively regulates lipogenic activity of liver X receptor.
    Kim GH; Oh GS; Yoon J; Lee GG; Lee KU; Kim SW
    J Clin Invest; 2015 Jan; 125(1):183-93. PubMed ID: 25437875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of 5α, 6α-epoxycholesterol as a novel modulator of liver X receptor activity.
    Berrodin TJ; Shen Q; Quinet EM; Yudt MR; Freedman LP; Nagpal S
    Mol Pharmacol; 2010 Dec; 78(6):1046-58. PubMed ID: 20837678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.